4 June 2019 - Ahead of the anticipated 2019 marketing of FDA-approved anticancer biosimilars in the United States, pharmacy benefit manager Magellan Rx Management today announced the launch of an oncology biosimilar program.

The initiative, says the PBM, focuses educating customers, members, and providers “through the implementation of individualized strategies that consider clinical, financial, and regulatory factors.” 

The result, indicated Magellan, will be to maintain or expand access to effective therapies while delivering savings for its participating customers.

Read Center for Biosimilars article